KalVista Pharmaceuticals, Inc. (KALV) closed the last trading session at $15.24, gaining 2.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.22 indicates an 118% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $5.52. While the lowest estimate of $22.00 indicates a 44.4% increase from the current price level, the most opti ...

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch. • KalVista Pharmaceuticals stock is approaching key resistance levels. Why did KALV hit a new high?In July 2025, the U.S. Food and Drug Administration (FDA) approved Ekterly for acute attacks of hereditary angioedema (HAE) in adult and pediatric pati ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...

With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:Greenbrier Companies Inc (NYSE:GBX) posted upbeat earnings for the first quarter, after the closing bell on Thursday. The company posted earnings of $1.14 per share, beating market estimates of 87 cents per share. The company's quarterly sales came in at $706.100 million versus expectations of $626.297 million, according to data from Benzinga Pro. Greenbrier shares slip ...

U.S. stock futures pared earlier losses to advance on Friday after a mixed Thursday. Futures of major benchmark indices were trading higher.Rising unrest in Iran gripped investor sentiment as WTI Crude futures rose, gold remained largely flat, and the silver spot was inching higher. With the Iranian government initiating a nationwide internet blackout to quell dissent, traders were parsing the risk on global markets and the economy.The U.S Supreme Court is set to announce its ruling on tariffs imposed on ot ...

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]

Financial Performance - EKTERLY® generated $13.7 million in net product revenue for the third quarter ended September 30, 2025[1]. - The company reported a net loss of $49.5 million for the three months ended September 30, 2025, compared to a net loss of $39.1 million in the same period of 2024[16]. - Research and development expenses decreased to $12.0 million from $18.7 million year-over-year, primarily due to reduced clinical trial expenses[16]. - Selling, general and administrative expenses increased to $46.5 million from $24.8 million year-over-year, driven by commercialization expenses related to EKTERLY[16]. - As of September 30, 2025, the company had approximately $309.2 million in cash, cash equivalents, and marketable securities, expected to fund operations through profitability[8]. Product Adoption and Market Expansion - 937 patient start forms were received in the US, indicating strong adoption as the first and only oral on-demand treatment for hereditary angioedema (HAE)[4]. - EKTERLY was launched in Germany in October 2025, with initial orders indicating encouraging demand[3]. - The company received regulatory approvals for EKTERLY in the US, EU, UK, Switzerland, and Australia, expanding its market reach[4]. - The company anticipates continued growth in patient starts and repeat prescriptions for EKTERLY, reflecting confidence in its clinical value[3]. Funding and Strategic Initiatives - The company successfully closed a $144 million convertible note offering to support its global launch strategy[3].

Core Insights - Jefferies has released a report on the outlook for the U.S. biotech industry in 2026, highlighting key clinical trial data disclosures, new drug approvals, and policy dynamics that could lead to value re-evaluation for companies in the sector [1] Six Preferred Stocks - Jefferies identified six companies as core recommendations for 2026 based on market catalysts and valuation potential: - Dianthus Therapeutics (DNTH.US), target price $66: Focused on claseprubart for various neuromuscular diseases, with peak revenue estimated at $2 billion [2] - Taysha Gene Therapies (TSHA.US), target price $11: TSHA-102 for Rett syndrome, with peak revenue potential of $2 billion and a key trial data disclosure expected by the end of 2026 [2] - Tyra Biosciences (TYRA.US), target price $32: Dabogratinib for bladder cancer and achondroplasia, with critical data expected next year [3] - Tango Therapeutics (TNGX.US), target price $14: Collaboration with Revolution Medicines for a pancreatic cancer treatment, with data expected in mid-2026 [3] - ORIC Pharmaceuticals (ORIC.US), target price $23: Two potential assets targeting prostate cancer and lung cancer, with key data expected next year [4] - Solid Biosciences (SLDB.US), target price $15: Focused on gene therapy for Duchenne muscular dystrophy, with critical meetings with the FDA planned for 2026 [4] Seven Undervalued Companies - The report also highlighted seven undervalued companies with significant catalysts: - Ultragenyx Pharmaceutical (RARE.US), target price $114: Expected key catalysts in 2026, including data for treatments for osteogenesis imperfecta and Angelman syndrome [5] - Beam Therapeutics (BEAM.US), target price $41: Updates on AATD therapy and SCD therapy expected in 2026, showcasing strong potential [5] - Aurinia Pharmaceuticals (AUPH.US), target price $21: Steady growth in lupus nephritis treatment, with new drug development paths expected to expand growth [6] - Kodiak Sciences (KOD.US), target price $39: Anticipated data from three pivotal trials in 2026, with significant potential for stock volatility [7] - Intellia Therapeutics (NTLA.US), target price $45: Key data for hereditary angioedema therapy expected in mid-2026, with sufficient cash reserves to support operations [7] - Compass Therapeutics (CMPX.US), target price $8: Data for cholangiocarcinoma therapy expected in early 2026, with a significant market opportunity [8] - KalVista Pharmaceuticals (KALV.US), target price $38: First oral treatment for hereditary angioedema expected to see rapid growth in 2026 [8] Five Potential Acquisition Targets - Jefferies identified five companies that may become acquisition targets in 2026 due to their unique assets or market positions: - Arrowhead Pharmaceuticals (ARWR.US): Strong RNAi product line for cardiovascular and metabolic diseases [9] - Celcuity (CELC.US): Unique efficacy of gedatolisib in breast cancer [9] - ORIC Pharmaceuticals: High-value prostate and lung cancer projects [9] - Travere Therapeutics (TVTX.US): Potential for significant market expansion in rare kidney diseases [9] - KalVista Pharmaceuticals: First-mover advantage in oral HAE treatment [9]

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in Japan. EKT. ...

PresentationHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce Ben Palleiko, the CEO of KalVista. It's a fireside chat format. Thanks so much for joining us today, Ben.Maury, thanks, as always, for the invite and grateful to Jefferies for all they've done with us over the years. So happy to be here.And maybe starting off, if you can give a 1-minute intro to the company for people who may not be familiar with the company.Benjamin PalleikoCEO & Di ...